VCYT — Veracyte, Inc.
$24.33
$-0.30 (-1.22%)
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
Market Cap
$1.96B
Forward P/E
15.5x
52-Week Range
N/A
VCYT Price History
Revenue vs. Net Income
$517M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$127M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
5.1%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
14.6x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
1.9%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+3.1%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
